12:36 PM
Jan 11, 2019
 |  BC Extra  |  Politics & Policy

Louisiana requests bids for subscription-based HCV model

Louisiana’s Department of Health took the next step Thursday in its subscription-based payment model, soliciting offers from drug manufacturers to negotiate five years of unrestricted access to an HCV therapy for its Medicaid and prison population.

The Department of Health, which hopes to have a partner in place by July 1, is seeking to treat over 10,000 of the 39,000 HCV patients among these groups by YE20.

To qualify, manufacturers must own a patent on at least one HCV therapy that has broad virologic coverage across populations. Applicants must also provide evidence of a supply chain and inventory system capable of producing, supplying and shipping product at the desired scale during the five-year term.

The deadline for offers is Feb. 28.

Under the new model, announced in 2018, the state would receive an unlimited supply of HCV drugs at a fixed price for a population that has remained largely untreated even as competition has pressed price tags down (see "The Louisiana Purchase").

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD